Lumida
/ELDN
⌘K
Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc

ELDN
$2.78USD+0.00%+0.00 today

MARKET CAP

225.9M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$1
$5

AI Summary

Stalk
TrimMedium

The asset remains in a high-confidence Stage 4 decline with a bearish medium-term bias and no mean-reversion support. Price trades below all key EMAs with persistent downward momentum. Until a corrective rally into the 50DMA/200DMA resistance zone and rejection is evident, sales should be deferred. The recommended execution is to Trim into structural rallies rather than aggressive selling into weakness.

  • 10-patient trial: 100% achieved insulin independence with no rejection
  • Analyst PT hike to $8.60 implies 126% gain from $3.81
  • Projected net loss of $0.88/sh next year vs. $0.56 last year
Full analysis →
Insider Trades2 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 31, 2026SellELDNSteven PerrinPresident72,138$3.38$225.9M-39.57%+105.93%$243.8K-47.04%Trim
Jul 31, 2026SellELDNDavid-Alexandre C GrosChief Executive Officer194,791$3.38$225.9M-39.57%+105.93%$658.4K-53.59%Trim